ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0391

High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time

Elizabeth Marjanovic1, Calvin Heal1, Tonia Moore1, Joanne Manning2, Sarah Wilkinson1, Graham Dinsdale2, Mark Dickinson1, Jack Wilkinson1, Ariane Herrick3 and Andrea Murray1, 1University of Manchester, Manchester, United Kingdom, 2Salford Royal NHS Foundation Trust, Manchester, United Kingdom, 3University of Manchester, Salford, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Imaging, Outcome measures, Raynaud's phenomenon, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: There are currently no validated objective measures of systemic sclerosis (SSc)-related skin thickening and this hampers clinical trials of potential new treatments. The modified Rodnan skin score (mRSS, the current gold standard) has limitations including concerns about inter-rater reliability. The aim of this study was to test the hypothesis that high frequency ultrasound (HFUS), which measures skin thickness is (a) sensitive to change and (b) correlates with local ‘skin score’ (criterion validity), both OMERACT criteria for validation.

Methods: In this prospective study, patients with early diffuse cutaneous SSc (dcSSc; duration of first non-Raynaud’s clinical manifestation < 5 years) underwent HFUS at each visit. Imaging was carried out at nine sites (most corresponding to sites assessed for mRSS; non-dominant ring finger, dorsum of hand, forearm, upper arm, forehead, anterior chest, abdomen, leg and dorsum of foot. Local skin score (0-3; 0 normal, 3 unable to move) was also assessed at each site. Images were assessed by one observer; skin thickness was measured as the distance from the surface of the skin to the base of the dermis (i.e. epidermis and dermis). The average thickness was taken of 3 measures made on each image at the left, centre and right in order to take into account any differences in thickness across the image (Figure 1). Longitudinal data underwent linear mixed effects modelling; a random intercept model with a Holm- Bonferroni correction applied.

Results: Seventeen patients with dcSSc were recruited (10 F:7M), median age 54 (range 42 to 61) years, median duration of Raynaud’s 2 (IQR 2- 5) years and duration of first non-Raynaud’s clinical manifestation 2 (1- 4) years. Three patients had 5 sets of measures, four had 4, four had 3, six had 2; median duration of follow-up of 16 months (range 7-43 months). Although patients did not follow a set pattern of change (i.e. skin thickness increased for some patients and sites and decreased for others) HFUS was sensitive to changes in thickness (example in Figure 2). Modelling indicated that changes in local skin score tracked well with changes in HFUS thickness measures at the dorsum of the hand, forearm, chest and leg (indicated by the local skin score coefficent in Table 1, p’< 0.05).

Conclusion: Conclusions

In patients with early dcSSc HFUS was able to determine differences in skin thickness with time, indicative of sensitivity to change.

Changes in skin thickness as measured by HFUS mirrored changes assessed by local palpation scores at several sites.

Patients at first visit had different levels of skin thickening due to the different durations and

severities of disease, this heterogeneity makes identifying patterns of change over time in patients difficult.

These findings support the hypothesis that HFUS is sensitive to change and shows criterion validity, showing promise for future validation of HFUS as an outcome measure in clinical trials.

Table 1: Imaging site, local skin (palpation) score co-efficient indicative of relationship between local palpation and HFUS (increase in coefficient indicative of positive relationship), confidence intervals and adjusted p value (p’); *p’<0.05.

Figure 1: Example of an HFUS image of the chest showing mark-ups on the left, centre and right. Numbers in white boxes along the top and side of the image represent mm.

Graph of skin thickness (mm) as measured by HFUS with time (months); each colour represents a patient.


Disclosures: E. Marjanovic, None; C. Heal, None; T. Moore, None; J. Manning, None; S. Wilkinson, None; G. Dinsdale, None; M. Dickinson, None; J. Wilkinson, None; A. Herrick, None; A. Murray, None.

To cite this abstract in AMA style:

Marjanovic E, Heal C, Moore T, Manning J, Wilkinson S, Dinsdale G, Dickinson M, Wilkinson J, Herrick A, Murray A. High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/high-frequency-ultrasound-imaging-of-skin-thickness-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis-an-objective-outcome-measure-to-track-change-over-time/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-frequency-ultrasound-imaging-of-skin-thickness-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis-an-objective-outcome-measure-to-track-change-over-time/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology